Börsipäev 19. november
Log in or create an account to leave a comment
-
Kuigi FOMC oktoobrikuu istungi protokoll midagi väga uut päevavalgele ei toonud, jättes detsembris intressimäära tõstmiseks ukse avatuks, vajasid turuosalised meeldetuletust, et otsused sõltuvad jooksvatest majandusnäitajatest ning et rahapoliitika normaliseerimine saab tulevikus olema aeglasem võrreldes varasemate tsüklitega viimaste aastakümnete jooksul. S&P 500 kerkis 1,6%, Euroopas jõudis Stoxx 600 enne sulguda -0,1% kaotusega
FOMC sõnumi varju jäänud USA kinnisvaraturu näitajad tekitasid erinevaid emotsioone. Uute majade alustatud ehitused kahanesid oktoobris -11,0% võrreldes septembriga, ületades analüütikute -3,8% prognoosi, kuid languse taga olid ühekordsed regionaalsed tegurid. Alustatud ehitused lõunas kukkusid MoM -18,6%, mida võisid mõjutada üleujutused oktoobri alguses ning läänes alanesid ehitused -16,2% pärast väga tugevat tõusu septembris (23,3%). Oktoobris väljastatud ehitusload kasvasid eelmise kuu baasil 4,1% annualiseeritult 1,150 miljonini, vastates laias laastus ootustele ning viidates sellele, et taastumine kinnisvarasektoris peaks edaspidi jätkuma.
Ralli Wall Streetil mõjus öösel positiivselt ka Aasia aktsiaturgudele, kus Jaapani, Hongkongi ja Hiina indeksid näitasid 0,7-1,2%protsendilist tõusu. Jaapanis otsustas keskpank jätkata rahabaasi suurendamist senises mahus (80 triljonit jeeni aastas), ühtides konsensuse ootusega. Ehkki riigi majandus on kaks kvartalit järjest languses olnud, kirjutab keskpank negatiivse mõju arenevate turgude jahtumise arvele, mida aitab kompenseerida kodumaise tarbimise jätkuv paranemine.
Tänastest majandusuudistest võiksid tähelepanu pälvida Suurbritannia oktoobrikuu jaemüük, USA möödunud nädala esmased töötu abiraha taotlused ning Philadelphia FEDi töötleva tööstuse aktiivsusindeks.
11.30 Suurbritannia jaemüük (oktoober)
14.30 Euroopa Keskpanga eelmise istungi protokoll
15.00 Venemaa jaemüük (oktoober)
15.30 USA esmased töötu abiraha taotlused
15.30 USA Philadelphia FEDi töötleva tööstuse küsitlus (november)
17.00 USA juhtivate indikaatorite indeks (oktoober)
19.30 FEDi Lockhart esineb kõnega
23.45 FEDi Fischer esineb kõnega -
Mõned jooksvad nopped Jaapanik keskpanga juhi pressikonverentsilt
KURODA: NO NEED TO CHANGE VIEW THAT PRICE EXPECTATIONS RISING
KURODA: FINAL DEMAND IN GDP GREW, GRADUAL RECOVERY CONTINUING
KURODA: BIGGEST FACTOR IN NEGATIVE GDP IN 3Q WAS INVENTORIES
KURODA: CONSUMPTION WAS FIRM, EXPORTS WERE GROWING IN GDP DATA
KURODA: TIMING OF REACHING 2% TARGET DEPENDS ON OIL
KURODA: EXPECT CPI TO REACH 2% AROUND 2H OF FY2016
KURODA: INFLATION EXPECTATIONS RISING IN LONGER-TERM VIEW
KURODA: VIRTUOUS ECONOMIC CYCLE IS WORKING IN JAPAN
KURODA: POSITIVE INVESTMENT STANCE CONTINUING IN JAPAN
KURODA: CONCERN ABOUT BALANCE SHEET WON'T STOP ANY MORE EASING
KURODA: DON'T SEE PROBLEMS ARISING IF CONTINUE CURRENT QQE
KURODA: IN LONG-TERM, IF WAGES DON'T RISE, PRICES WON'T RISE
KURODA: NEXT SPRING WAGES TALKS ARE VERY IMPORTANT
KURODA: EXPECT HIGH JAPAN CORPORATE PROFITS TO CONTINUE
KURODA: EXPECT CAPEX TO INCREASE, EVEN IF A BIT DELAYED -
Täna alustab kauplemist sümboli SQ all Square Inc. IPO osalemise märkimisvahemik oli 11-13 USD, märkimishinnaks kujunes aga 9 USD.
-
Suurbritannia jaemüük kahanes oktoobris autosid arvestamata MoM -0,9% vs oodatud -0,6% ning seda nõrgemaks revideeritud baasi pealt (1,7% pealt 1,5% peale). Aastatagusega võrreldes aeglustus kasv 3,0% peale. Jaemüük kipub olema üsna volatiilne näitaja, sõltudes muuhulgas ilmast ning tõenäoliselt tänane number keskpanga arvamust Suurbritannia majanduse väljavaate osas ei muuda.
-
USA möödunud nädala töötu abiraha taotlused vastasid ootusele. Erinevalt NY töötleva tööstuse aktiivsusest, osutus Philadelhpia FEDi küsitluse järgi sealne ärikliima paranemine arvatust kiiremaks.
USA Initial Jobless Claims for Oct 13 271.0K vs 271.0K consensus estimate; Prior reading was 276.0K
Philadelphia Fed Business Outlook (Nov): 1.9 (est -0.5, prev -4.5) -
Gapping up
In reaction to strong earnings/guidance: GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%
M&A news: CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)
Select small cap biotech related names showing strength: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%
Select metals/mining stocks trading higher: MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%
Other news: KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)
Analyst comments: TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
Gapping down
In reaction to disappointing earnings/guidance: LQDT -16.2%, SSI -11.5%, EDAP -10.1%, JKS -8.2%, SMTC -7.5%, UNH -6.1%, BBY -4.2%, BKE -1.5%, SMRT -1.2%, IGLD -1%
M&A news: SYT -2.3% (cont volatility surrounding M&A spec)
Other news: NBG -17.1% (cont weakness), AMAG -10.2% (received Complete Response Letter from the FDA for Makena (hydroxyprogesterone caproate injection) for the reduction of the risk of preterm birth), VLP -9.1% (announces an underwritten public offering of 4.25 mln units ), SUNE -4.9% (Blackstone denying speculation related to debt investment), AET -4.1% (in symp with UNH), RDY -2.8% ( issues statement related to recent media reports; co states it has always adhered to international accounting practices), HUM -2.4% (in symp with UNH), AGN -1.8% (Allergan, Pfizer (PFE) near a deal under which Pfizer would acquire Allergan for as much as $380/share, according to BloombergWSJ reporting Treasury Department might issue anti inversion tax rules this week), DVA -1.6% (co's subsidiary received Civil Investigative Demand from the U.S. Department of Justice), RMAX -1.6% (prices secondary offering of 4,500,000 shares of common stock by its controlling stockholder, RIHI, at $36.00 per share), EQIX -1.6% (prices offering of 2,604,167 shares of common stock at $288.00 per share), BFAM -1.5% (announces pricing of its 3.65 mln share secondary offering by selling stockholders at $63.80/share)
Analyst comments: TWI -7.7% (downgraded to Sell from Neutral at Goldman )
Allikas: Briefing.com -
oktoobris on Caterpillari masinate müügistatistika nõrgenenud kõikides regioonides
